Clinical Trial: A Phase I Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients with CAIX-positive Cancer

U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06840548) titled 'A Phase I Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients with CAIX-positive Cancer' on Feb. 17.

Brief Summary: Phase I and multicenter study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with clear cell renal cell carcinoma.

Study Start Date: Feb., 2025

Study Type: INTERVENTIONAL

Condition: Clear Cell Renal Cell Carcinoma (ccRCC)

Intervention: DRUG: [68Ga]Ga-OncoCAIX

All patients will receive a single intravenous bolus administration.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Philogen S.p.A.

Published by HT Digital Content Services with permission from Health Daily Digest....